Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 159,900 shares at $157.67 ($25.4M) on 2023-04-12, disclosed to the SEC on 2023-04-14.
Scheduled sale ($25.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $155.67 | 12,634 | $2.0M | 7.7% |
| 2 | $155.67 | 12,634 | $2.0M | 7.7% |
| 3 | $156.69 | 16,650 | $2.6M | 10.3% |
| 4 | $156.69 | 16,650 | $2.6M | 10.3% |
| 5 | $157.67 | 8,334 | $1.3M | 5.2% |
| 6 | $157.67 | 8,334 |
| $1.3M |
| 5.2% |
| 7 | $158.56 | 2,382 | $378K | 1.5% |
| 8 | $158.56 | 2,382 | $378K | 1.5% |
| 9 | $160.63 | 30,456 | $4.9M | 19.3% |
| 10 | $160.63 | 30,456 | $4.9M | 19.3% |
| 11 | $161.16 | 9,444 | $1.5M | 6.0% |
| 12 | $161.16 | 9,444 | $1.5M | 6.0% |
| 13 | $161.98 | 100 | $16K | 0.1% |
| Total | $158.72 avg | 159,900 | $25.4M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |